The recommended dose of omalizumab for the treatment of chronic spontaneous urticaria (CSU) is 300 mg every 4 weeks, but there is no recommendation for patients who do not benefit from this dose. Our aim is to present the experiences on the use of doses of omalizumab higher than those recommended for CSU patients and to propose a protocol for updosing. This was a retrospective analysis of patients treated with omalizumab for CSU from 2 urticaria centers in Istanbul and Barcelona. The weekly urticaria activity score and/or the Urticaria Control Test (UCT) were used to monitor response. In Barcelona, a stepwise updosing regimen was preferred (450 mg first, then increasing to 600 mg), while in Istanbul, direct updosing to 600 mg was chosen. In Istanbul, 81 (88%) patients were treated with 300 mg, while 11 (12%) received 600 mg of omalizumab. In Barcelona, 7 (8.8%), 45 (56.3%), 17 (21.3%), and 11 (13.8%) patients received 150, 300, 450, and 600 mg of omalizumab, respectively. Urticaria control was achieved in 82.6% of the patients with 300 mg and in 8.7% of the patients with 600 mg in Istanbul, while it was achieved with 150 mg in 10%, with 300 mg in 48.8%, with 450 mg in 16.3%, and with 600 mg in 6.3% of the patients in Barcelona. In total, 123 (71.5%) patients responded to 150-300 mg and 26 (15.1%) to 450-600 mg. When responders to 150-300 mg (n = 123) were compared with responders to 450-600 mg (n = 26), BMI was found to be higher, and pre-omalizumab UCT was found to be lower in patients receiving updosed omalizumab (p = 0.029). Baseline data of the patients, especially BMI and pre-oma UCT, might be useful to determine if the patient will require higher doses of omalizumab. We recommend a stepwise approach starting from 450 mg and then updosing to 600 mg in CSU patients who do not respond or partially respond to 300 mg of omalizumab after 3-6 months of treatment.
Introduction
Chronic spontaneous urticaria (CSU) is characterized by recurrent wheals and/or angioedema for longer than 6 weeks [1] . Symptomatic treatment consists of a stepwise approach starting with nonsedating antihistamines, up- dosing antihistamines up to four-fold, followed by omalizumab, cyclosporine, or leukotriene antagonists [1] . The recommended dose of omalizumab for the treatment of CSU is 300 mg every 4 weeks, which is the preferred approach for most treating physicians, but there is no recommendation for the patients who do not benefit from 300 mg every 4 weeks. Our aim was to present the experiences of 2 urticaria specialist centers on the use of doses of omalizumab higher than those recommended for CSU patients who failed to respond after 3-6 administrations of 300 mg every 4 weeks.
Materials and Methods
We conducted a retrospective analysis of the response rates and safety profiles of updosing omalizumab in refractory CSU to 300 mg every 4 weeks. Ninety-two and 80 CSU patients on follow-up from 2 urticaria specialist centers in Istanbul and Barcelona, respectively, were analyzed from May 2014 to March 2017. CSU patients receiving at least 6 administrations of omalizumab were included in the analysis. The weekly urticaria activity score (UAS7) and/or the Urticaria Control Test (UCT) were used to monitor the response. Urticaria control was defined as having UCT ≥12, wellcontrolled activity as UAS7 < 6, and complete control and controlled activity was defined as UCT = 16 and UAS7 = 0 [2, 3] .
In Barcelona, a stepwise updosing regimen was preferred (450 mg first, then increasing to 600 mg if there was no response), while in Istanbul, direct updosing to 600 mg was chosen. Of note, the treatments were given monthly in Barcelona but on a two-weekly basis in Istanbul (2 patients preferred 600 mg monthly). An analysis of the demographic data as well as a comparison between the patients responding to 150-300 mg and 450-600 mg was performed with regard to gender, age, duration of disease, BMI, angioedema, associated chronic inducible urticaria, total IgE levels, pre-omalizumab UAS7 (pre-oma UAS7), and pre-oma UCT scores. We also analyzed whether nonresponders or partial responders would benefit from updosing. The criteria to define patients as minimal responders were a minimal change of 3 points in UCT and 11 points in UAS7 from baseline to the 6th month of treatment [3, 4] . Nonresponders were defined as those without any of the improvements described.
Results
The demographic characteristics of patients are shown in Table 1 . In Istanbul, 81 (88%) patients were treated with 300 mg monthly, while 11 (12%) received 600 mg of omalizumab (300 mg at 2-week intervals). In Barcelona, 7 (8.8%) received 150 mg, 45 (56.3%) received 300 mg, 17 (21.3%) received 450 mg, and 11 (13.8%) received 600 mg of monthly omalizumab injections (Table 2) . Urticaria control was achieved in 82.6% of the patients with 300 mg and in 8.7% of the patients with 600 mg in Istanbul, while it was achieved with 150 mg in 10%, with 300 mg in 48.8%, with 450 mg in 16.3%, and with 600 mg in 6.3% of the patients in Barcelona. At the 12th week of updosing, urticaria control was achieved by 76.4% (13/17) of the patients given 450 mg and by 45.4% (5/11) of the patients given 600 mg in Barcelona, while it was achieved by 72.7% (8/11) of the patients given 600 mg in Istanbul. In total, out of 182 patients, 39 (21.4%) patients received 450-600 mg. Of them, 13 (7.1%) responded to 450 mg, 13 (7.1%) responded to 600 mg, and 13 (7.1%) did not respond. Complete control (UCT = 16, UAS7 = 0) was achieved by 67.4% in Istanbul and 44.7% in Barcelona. After updosing, only The number of injections before updosing ranged between 4 and 9 (mean = 7) in Istanbul and between 3 and 11 (mean = 5) in Barcelona. When patients who responded to 150-300 mg (n = 123) were compared with responders to 450-600 mg (n = 26), the duration of disease and angioedema frequency was found to be higher in patients receiving approved doses (p = 0.003, p = 0.03, and p = 0.000), while BMI was higher and pre-oma UCT was lower in patients receiving updosed omalizumab (p = 0,029) ( Table 3) . Only minor side effects were reported in 2 of the patients receiving 600 mg of omalizumab in both centers (1 arthralgia at the Istanbul center and 1 nausea and myalgia at the Barcelona center). We could include only 19 patients to define the minimal responders who had pre-oma and the 6-month UCT or UAS7 data. The classification of the patients according to their responses before updosing re- vealed 4 patient categories: 8 patients had a minimal response with omalizumab between 0 and 6 months and benefited from updosing, 2 had a minimal response but did not benefit from updosing, 5 did not have a minimal response but benefited from updosing, and 4 did not have a minimal response and did not benefit from updosing.
Discussion
Even though omalizumab 300 and 600 mg showed similar efficacy in a phase 2 study [5] , experiences from real life point to better response rates in some patients who were given 300 mg in 2-week intervals [6] . In our study, the analysis of real-life data from 2 urticaria centers showed that updosing omalizumab to 450-600 mg might be necessary in some CSU patients treated with omalizumab; approximately 35% of the patients from Barcelona and 12% of the patients from Istanbul received omalizumab doses higher than those approved.
Updosing omalizumab (450-600 mg, given 300 mg in 2-week intervals or 450-600 mg in 4-week intervals) led to symptom control in approximately 15% (8.7 and 22.6% from Istanbul and Barcelona, respectively) of the patients who would otherwise have remained uncontrolled with the approved doses. Patients with a higher BMI and lower baseline UCT scores were found to require higher doses to control the disease in our series. In asthma, the recommended dose of omalizumab changes according to the body weight of the patient, while a fixed dose regimen is recommended for CSU regardless of the body weight and total IgE levels [7] . Since the average BMI of the patients who required updosing was found to be 30, our results indicate the necessity of dose adjustment according to the BMI of the patients; dose enhancement might be required especially in patients with a BMI higher than 30.
The pre-oma UCT was found to be lower in patients requiring updosing of omalizumab (2 vs. 4; p = 0.000). The UCT has been an established instrument to monitor the response to treatment or disease control, but UCT as a baseline patient assessment criterion has not been mentioned previously. It was interesting to find that not preoma UAS7 but pre-oma UCT defined the need for updosing. This might be attributed to the superiority of this tool, which combines disease activity with quality of life.
As mentioned above, the updosing regimen differed between the centers: stepwise with first 450 and then 600 mg in Barcelona, and directly to 600 mg in Istanbul. At the 12th week of updosing, urticaria control was achieved by 76.4% (13/17) of the patients given 450 mg and by 45.4% (5/11) of the patients given 600 mg in Barcelona, while it was achieved by 72.7% (8/11) of the patients given 600 mg in Istanbul. In total, of the 39 patients, 13 responded to 450 mg and 13 responded to 600 mg (8 of whom were directly started on 600 mg). It could be speculated that given the high rate of responders to 450 mg, the responders of 600 mg in Istanbul could also be responders to 450 mg, and the nonresponders to 600 mg in Barcelona were the very resistant cases left in the end. The total response rate to updosing was 8/11 (72.7%) in Istanbul compared to 18/28 (64.3%) in Barcelona. The difference might be due to (1) the more severely affected patients in Barcelona, (2) the 2-weekly regimen in Istanbul, or (3) the higher doses given in Istanbul.
The average number of injections before updosing was 7 (4-9) in Istanbul and 5 (3-11) in Barcelona, which approximates to 6 when the data is combined. This observation is in line with an expert review that recommends updosing omalizumab in patients not responding to treatment after 6 months [8] . From the analysis of patients' response patterns before updosing we might speculate that patients with some response to omalizumab from the beginning might have greater benefit from updosing, but still there were patients who benefited from updosing even without a minimal response from the beginning of treatment. Briefly, the classification of the benefit before updosing did not forecast response.
Our study has several strengths and limitations. First, it is a retrospective analysis, and no preset protocols for updosing have been implemented; the characteristics and disease severity of the patients from the centers were different. However, the different protocols from the centers gave the opportunity to compare the advantages and disadvantages of these protocols.
From our clinical experience, we conclude that the baseline data of the patient, especially BMI and pre-oma UCT, might be useful to determine if the patient will require higher doses of omalizumab. We recommend a stepwise approach starting from 450 mg and then updosing to 600 mg if there is no response after 3 months of treatment in CSU patients who do not respond or partially respond to 300 mg of omalizumab after 3-6 months of treatment. Further studies and larger series from multiple centers are required to define a protocol for the implementation of higher doses of omalizumab in CSU patients.
